Deferred Tax Assets, Valuation Allowance of Aprea Therapeutics, Inc. from 31 Dec 2018 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Aprea Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2018 to 31 Dec 2024.
  • Aprea Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $50,165,532, a 1.5% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Aprea Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $50,165,532 +$721,673 +1.5% 31 Dec 2024 10-K 25 Mar 2025 2024 FY
Q4 2023 $49,443,859 +$5,814,170 +13% 31 Dec 2023 10-K 25 Mar 2025 2024 FY
Q4 2022 $43,629,689 +$1,514,146 +3.6% 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q4 2021 $42,115,543 +$8,574,010 +26% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q4 2020 $33,541,533 +$13,864,739 +70% 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q4 2019 $19,676,794 +$7,014,920 +55% 31 Dec 2019 10-K 16 Mar 2021 2020 FY
Q4 2018 $12,661,874 31 Dec 2018 10-K 27 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.